PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32430093-4 2020 This study describes the mechanistic analyses of the novel anthracycline, pivarubicin, and its in vivo efficacy against human primary TNBC.

Pivarubicin directly activates PKC-delta, triggers rapid mitochondrial-dependent apoptosis and circumvents resistance conferred by overexpression of P-glycoprotein, Bcl-2, Bcl-XL and Bcr-Abl. Anthracyclines 59-72 ATP binding cassette subfamily B member 1 Homo sapiens 295-309 32158919-2 2020 We recently identified an ABCB1 enhancer that is activated in response to a range of cellular stressors, including anthracycline chemotherapy. Anthracyclines 115-128 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 30538383-0 2018 P-Glycoprotein Expression in Indian Breast Cancer Patients with Reference to Molecular Subtypes and Response to Anthracycline-Based Chemotherapy-a Prospective Clinical Study from a Developing Country. Anthracyclines 112-125 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 28763429-10 2017 We replicated association, P<0.05, with SNPs previously associated with anthracycline-induced cardiotoxicity at CBR3 and ABCB1. Anthracyclines 75-88 ATP binding cassette subfamily B member 1 Homo sapiens 124-129 29090664-7 2018 In addition, genetic variability in the transporters of anthracyclines could affect the intake in cells, including influx (SLC28A3, SLC22A12, SLCO1B1) and efflux transporters (ABCB1, ABCC1, ABCC3, ABCG2). Anthracyclines 56-70 ATP binding cassette subfamily B member 1 Homo sapiens 176-181 29162041-7 2017 Anthracycline cardiac toxicity may depend on the association with drugs that inhibit or induce placental P-glycoprotein (P-gp). Anthracyclines 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 105-119 29162041-7 2017 Anthracycline cardiac toxicity may depend on the association with drugs that inhibit or induce placental P-glycoprotein (P-gp). Anthracyclines 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 29145976-6 2017 Many studies show that upon repeated treatment schedules of cell cultures or tumors with taxenes and anthracyclines as well as other chemotherapeutic drugs, amplification, and/or overexpression of a series of genes genomically surrounding the ABCB1 locus, is observed. Anthracyclines 101-115 ATP binding cassette subfamily B member 1 Homo sapiens 243-248 24678978-7 2015 P-gp has been found to be an important factor with regard to drug resistance in many of the drug classes used in the treatment of MM (proteasome inhibitors, anthracyclines, alkylating agents and immunomodulators are examples). Anthracyclines 157-171 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 27725879-2 2016 In the present study, we applied the CRISPR/Cas9 system to target ABCB1 (also named MDR1) gene which encodes a 170 kDa transmembrane glycoprotein (P-glycoprotein/P-gp) transporting multiple types of chemotherapeutic drugs including taxanes, epipodophyllotoxins, vinca alkaloids and anthracyclines out of cells to contribute multidrug resistance (MDR) in cancer cells. Anthracyclines 282-296 ATP binding cassette subfamily B member 1 Homo sapiens 66-71 27725879-2 2016 In the present study, we applied the CRISPR/Cas9 system to target ABCB1 (also named MDR1) gene which encodes a 170 kDa transmembrane glycoprotein (P-glycoprotein/P-gp) transporting multiple types of chemotherapeutic drugs including taxanes, epipodophyllotoxins, vinca alkaloids and anthracyclines out of cells to contribute multidrug resistance (MDR) in cancer cells. Anthracyclines 282-296 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 26799497-0 2016 Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Anthracyclines 169-183 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 27795507-8 2016 P-glycoprotein resistant anthracyclines, etoposide, or hematopoietic stem cell transplantations are increasingly applied to improve outcomes, but no standard treatment approach has yet been established. Anthracyclines 25-39 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 25685543-5 2015 Accordingly, P-gp inhibitors/blockers are potential enhancer for the cellular bioavailability of several clinically important anticancer drugs such as, anthracyclines, taxanes, vinca alkaloids, and podophyllotoxins. Anthracyclines 152-166 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 29145976-2 2017 Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and in particular of ABCB1 (P-glycoprotein or MDR1) is a well-known resistance mechanism for a plethora of cancer chemotherapeutics including for example taxenes, anthracyclines, Vinca alkaloids, and epipodopyllotoxins, demonstrated by a large array of published papers, both in tumor cell lines and in a variety of tumors, including various solid tumors and hematological malignancies. Anthracyclines 228-242 ATP binding cassette subfamily B member 1 Homo sapiens 86-91 29145976-2 2017 Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and in particular of ABCB1 (P-glycoprotein or MDR1) is a well-known resistance mechanism for a plethora of cancer chemotherapeutics including for example taxenes, anthracyclines, Vinca alkaloids, and epipodopyllotoxins, demonstrated by a large array of published papers, both in tumor cell lines and in a variety of tumors, including various solid tumors and hematological malignancies. Anthracyclines 228-242 ATP binding cassette subfamily B member 1 Homo sapiens 93-107 29145976-2 2017 Overexpression of a wide-spectrum of ATP-dependent efflux pumps, and in particular of ABCB1 (P-glycoprotein or MDR1) is a well-known resistance mechanism for a plethora of cancer chemotherapeutics including for example taxenes, anthracyclines, Vinca alkaloids, and epipodopyllotoxins, demonstrated by a large array of published papers, both in tumor cell lines and in a variety of tumors, including various solid tumors and hematological malignancies. Anthracyclines 228-242 ATP binding cassette subfamily B member 1 Homo sapiens 111-115 27545834-1 2016 This study evaluated the effect of electron beam irradiation on the cytotoxic activity of anthracycline antibiotics such as doxorubicin (DOX), epirubicin (EPI), and dunorubicin (DAU) in human acute lymphoblastic leukemia cell line CCRF-CEM and its multidrug-resistant variant CCRF-VCR1000 cell line characterized by the overexpression of ABCB1 gene. Anthracyclines 90-103 ATP binding cassette subfamily B member 1 Homo sapiens 338-343 25788263-5 2015 Clinical data showed a significant positive relationship between Cbl-b expression and survival in P-gp positive breast cancer patients who received anthracycline-based chemotherapy. Anthracyclines 148-161 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 25567217-0 2015 Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia. Anthracyclines 63-76 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 20944122-2 2010 We tested the assumption that anthracycline-induced P-gp and Caveolin-1 have correlated effects on cholesterol distribution in plasma membrane. Anthracyclines 30-43 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 23707158-1 2013 BACKGROUND: Transportation of anticancer drugs such as anthracyclines across the membrane is regulated by P-glycoprotein encoded by the human multidrug resistance gene 1 (ABCB1). Anthracyclines 55-69 ATP binding cassette subfamily B member 1 Homo sapiens 171-176 23768637-8 2013 P-glycoprotein is a product of the multidrug resistance (MDR1) gene, which is a major cause of the refractoriness of malignant lymphomas to conventional chemotherapeutic regimens containing anthracycline. Anthracyclines 190-203 ATP binding cassette subfamily B member 1 Homo sapiens 57-61 21374643-2 2012 Cellular overproduction of P-glycoprotein (P-gp), which acts as an efflux pump for various anticancer drugs (e.g. anthracyclines, Vinca alkaloids, taxanes, epipodophyllotoxins, and some of the newer antitumor drugs) is one of the more relevant mechanisms underlying MDR. Anthracyclines 114-128 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 21374643-2 2012 Cellular overproduction of P-glycoprotein (P-gp), which acts as an efflux pump for various anticancer drugs (e.g. anthracyclines, Vinca alkaloids, taxanes, epipodophyllotoxins, and some of the newer antitumor drugs) is one of the more relevant mechanisms underlying MDR. Anthracyclines 114-128 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 22158944-1 2012 Resistance to anthracyclines and other chemotherapeutics due to P-glycoprotein (pgp)-mediated export is a frequent problem in cancer treatment. Anthracyclines 14-28 ATP binding cassette subfamily B member 1 Homo sapiens 64-78 22158944-1 2012 Resistance to anthracyclines and other chemotherapeutics due to P-glycoprotein (pgp)-mediated export is a frequent problem in cancer treatment. Anthracyclines 14-28 ATP binding cassette subfamily B member 1 Homo sapiens 80-83 22986993-0 2012 Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein. Anthracyclines 33-47 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 22986993-4 2012 METHODS AND RESULTS: We found that Twist can regulate the expression of P-gp and then confer resistance to anthracycline drugs in human bladder cancer cells. Anthracyclines 107-120 ATP binding cassette subfamily B member 1 Homo sapiens 72-76 22986993-5 2012 Firstly, Twist was found to be coexpressed with P-gp in human bladder cancer cells and tissues, which were associated with enhanced chemoresistance to anthracycline drugs. Anthracyclines 151-164 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 22986993-7 2012 Bladder cancer cells that survived transient exposure to anthracycline drugs showed higher levels of P-gp expression and more nuclear localization of Twist than untreated cells. Anthracyclines 57-70 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 22986993-8 2012 CONCLUSION: We report a novel mechanism of anthracycline chemoresistance in bladder cancer in which activated Twist mediates P-gp expression in addition to its antiapoptotic roles. Anthracyclines 43-56 ATP binding cassette subfamily B member 1 Homo sapiens 125-129 24574923-0 2014 The connection between the toxicity of anthracyclines and their ability to modulate the P-glycoprotein-mediated transport in A549, HepG2, and MCF-7 cells. Anthracyclines 39-53 ATP binding cassette subfamily B member 1 Homo sapiens 88-102 22310978-9 2012 CONCLUSIONS: These results suggest that polymorphisms in GSTP1 and MDR1 may help to predict clinical response and DFS of anthracycline-based chemotherapy, and a polygenic pathway approach should provide more useful information. Anthracyclines 121-134 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 19088019-6 2008 For anthracyclines, polymorphisms in genes such as carbonyl reductase 3 (CBR3), ATP-binding cassette subfamily B, member 1 (ABCB1), glutathione-related transporter genes, and oxidative stress-related genes have been reported to correlate with clinical outcomes. Anthracyclines 4-18 ATP binding cassette subfamily B member 1 Homo sapiens 80-122 19440163-5 2009 Also associated with the onset or magnitude of anthracycline resistance were genes involved in drug transport (ABCB1, ABCC1), cell signaling and transcription (RDC1, CXCR4), cell proliferation or apoptosis (BMP7, CAV1), protection from reactive oxygen species (AKR1C2, AKR1C3, FTL, FTH, TXNRD1, MT2A), and structural or immune system proteins (IFI30, STMN1). Anthracyclines 47-60 ATP binding cassette subfamily B member 1 Homo sapiens 111-116 19470292-13 2009 This paper presents an overview of the investigations on the feasibility and application of flavonoids as P-gp modulators for improved efficacy of anti-cancer drugs like taxanes, anthracyclines, epipodophyllotoxins, camptothecins and vinca alkaloids. Anthracyclines 179-193 ATP binding cassette subfamily B member 1 Homo sapiens 106-110 19129072-12 2008 ABCB1 gene induction decreases disease-free and overall survival in patients with locally advanced breast cancer due to anthracycline resistance. Anthracyclines 120-133 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 17620438-1 2007 The multidrug resistance gene 1 (MDR1) product, P-glycoprotein (P-gp), pumps out a variety of anticancer agents from the cell, including anthracyclines, Vinca alkaloids, and taxanes. Anthracyclines 137-151 ATP binding cassette subfamily B member 1 Homo sapiens 4-31 19151448-4 2008 RESULTS: the polymorphism of MDR1 gene at cDNA position 3435 located in exon 26 has been shown to be correlated with clinical response to Anthracycline chemotherapy in breast cancer patients, without being affected by the positive or negative Her-2 expression. Anthracyclines 138-151 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 19151448-6 2008 CONCLUSION: breast cancer patients with positive Her-2 expression do not always respond to Anthracycline, it means that only patients with T/T genotype at position 3435 located in exon 26 of MDR1 gene have clinical response, while patients have C/T genotype do not show clinical response. Anthracyclines 91-104 ATP binding cassette subfamily B member 1 Homo sapiens 191-195 17483874-3 2007 Anthracyclines are especially prone to induction of resistance by the P-gp mechanism. Anthracyclines 0-14 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 17620438-1 2007 The multidrug resistance gene 1 (MDR1) product, P-glycoprotein (P-gp), pumps out a variety of anticancer agents from the cell, including anthracyclines, Vinca alkaloids, and taxanes. Anthracyclines 137-151 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 17620438-1 2007 The multidrug resistance gene 1 (MDR1) product, P-glycoprotein (P-gp), pumps out a variety of anticancer agents from the cell, including anthracyclines, Vinca alkaloids, and taxanes. Anthracyclines 137-151 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 17620438-1 2007 The multidrug resistance gene 1 (MDR1) product, P-glycoprotein (P-gp), pumps out a variety of anticancer agents from the cell, including anthracyclines, Vinca alkaloids, and taxanes. Anthracyclines 137-151 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 17256837-3 2007 Among them, compound 1d, on anthracycline-resistant erythroleukemia K562 cells, is able to completely reverse Pgp-dependent MDR at low nanomolar concentration. Anthracyclines 28-41 ATP binding cassette subfamily B member 1 Homo sapiens 110-113 16642371-2 2007 Sulindac has been shown to be a competitive substrate for the clinically important resistance protein, multi-drug resistance protein-1 (MRP-1), and thus might enhance the anti-cancer activity of substrate chemotherapeutic agents, e.g. anthracyclines. Anthracyclines 235-249 ATP binding cassette subfamily B member 1 Homo sapiens 103-134 16642371-2 2007 Sulindac has been shown to be a competitive substrate for the clinically important resistance protein, multi-drug resistance protein-1 (MRP-1), and thus might enhance the anti-cancer activity of substrate chemotherapeutic agents, e.g. anthracyclines. Anthracyclines 235-249 ATP binding cassette subfamily B member 1 Homo sapiens 136-141 16451059-3 2006 We hypothesize that direct modifications of the sugar moiety of anthracyclines avert P-glycoprotein (P-gp) recognition and efflux, increase drug intracellular concentration in cancer cells, and thus overcome P-gp-mediated drug resistance. Anthracyclines 64-78 ATP binding cassette subfamily B member 1 Homo sapiens 85-99 23506066-7 2006 Additionally, recent sugar modifications of anthracyclines have also been found to overcome P-glycoprotein-mediated drug resistance in cancer therapy. Anthracyclines 44-58 ATP binding cassette subfamily B member 1 Homo sapiens 92-106 23506066-9 2006 To finally find the "better" anthracycline, further areas of research still need to be explored such as: the elucidation of the topoisomerase and P-glycoprotein crystal structures, molecular modelling based on crystal structure in order to design the next generation of better anthracycline drugs, the continued modifications of the anthracycline sugar moieties, and the further improvement of anthracycline drug delivery methods. Anthracyclines 29-42 ATP binding cassette subfamily B member 1 Homo sapiens 146-160 16842217-8 2006 Other approaches to multidrug resistance reversal have also been considered: encapsulation of anthracyclines in liposomes or other carriers which deliver these drugs selectively to tumor tissues, the use of P-gp targeted antibodies such as UIC2 or the use of antisense strategies targeting the MDR1 messenger RNA. Anthracyclines 94-108 ATP binding cassette subfamily B member 1 Homo sapiens 294-298 16001170-3 2006 Among the mechanisms that can account for cell sensitivity to anthracyclines, there is an overexpression of drug transport proteins, like the transmembrane P-glycoprotein (PGP), the multidrug- resistance-related protein (MRP) and the lung-resistance-related protein (LRP). Anthracyclines 62-76 ATP binding cassette subfamily B member 1 Homo sapiens 156-170 16001170-3 2006 Among the mechanisms that can account for cell sensitivity to anthracyclines, there is an overexpression of drug transport proteins, like the transmembrane P-glycoprotein (PGP), the multidrug- resistance-related protein (MRP) and the lung-resistance-related protein (LRP). Anthracyclines 62-76 ATP binding cassette subfamily B member 1 Homo sapiens 172-175 16521213-11 2006 CONCLUSION: The chemotherapeutic efficacy with an anthracycline drug for advanced HCC can be predicted by immunohistochemical analysis of PGP expression. Anthracyclines 50-63 ATP binding cassette subfamily B member 1 Homo sapiens 138-141 16451059-3 2006 We hypothesize that direct modifications of the sugar moiety of anthracyclines avert P-glycoprotein (P-gp) recognition and efflux, increase drug intracellular concentration in cancer cells, and thus overcome P-gp-mediated drug resistance. Anthracyclines 64-78 ATP binding cassette subfamily B member 1 Homo sapiens 101-105 16451059-3 2006 We hypothesize that direct modifications of the sugar moiety of anthracyclines avert P-glycoprotein (P-gp) recognition and efflux, increase drug intracellular concentration in cancer cells, and thus overcome P-gp-mediated drug resistance. Anthracyclines 64-78 ATP binding cassette subfamily B member 1 Homo sapiens 208-212 16451059-11 2006 These data suggest that sugar modifications of anthracyclines avert P-gp binding, abolish P-gp-mediated drug efflux, increase intracellular drug concentration, and thus overcome P-gp-mediated drug resistance in cancer therapy. Anthracyclines 47-61 ATP binding cassette subfamily B member 1 Homo sapiens 68-72 16451059-11 2006 These data suggest that sugar modifications of anthracyclines avert P-gp binding, abolish P-gp-mediated drug efflux, increase intracellular drug concentration, and thus overcome P-gp-mediated drug resistance in cancer therapy. Anthracyclines 47-61 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 16451059-11 2006 These data suggest that sugar modifications of anthracyclines avert P-gp binding, abolish P-gp-mediated drug efflux, increase intracellular drug concentration, and thus overcome P-gp-mediated drug resistance in cancer therapy. Anthracyclines 47-61 ATP binding cassette subfamily B member 1 Homo sapiens 90-94 18528466-10 2006 We also discovered that p53 could regulate the expression of multidrug resistance protein-1 (MRP1), a member of the ABC family of transporters that mediates the sensitivity to vinca alkaloids and anthracyclines. Anthracyclines 196-210 ATP binding cassette subfamily B member 1 Homo sapiens 61-91 18528466-10 2006 We also discovered that p53 could regulate the expression of multidrug resistance protein-1 (MRP1), a member of the ABC family of transporters that mediates the sensitivity to vinca alkaloids and anthracyclines. Anthracyclines 196-210 ATP binding cassette subfamily B member 1 Homo sapiens 93-97 14499178-5 2003 Structure-activity relationship experiments have shown that the positively charged amino group of the anthracyclines could be responsible for their transport by P-gp. Anthracyclines 102-116 ATP binding cassette subfamily B member 1 Homo sapiens 161-165 16159384-11 2005 CONCLUSION: Our data indicate that anthracyclines inhibit the 26S proteasome as well as P-glycoprotein. Anthracyclines 35-49 ATP binding cassette subfamily B member 1 Homo sapiens 88-102 14981994-8 2003 The strong placental expression of P-glycoprotein may play a major role in limiting fetal exposure to anthracyclines and taxanes. Anthracyclines 102-116 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 15963852-7 2005 CONCLUSION: Using chronic myeloid leukemia as a model, we show that PgP-mediated resistance to imatinib and anthracyclines can be durably reversed by nonviral, transposon-based knockdown of PgP in malignant cells. Anthracyclines 108-122 ATP binding cassette subfamily B member 1 Homo sapiens 68-71 15963852-7 2005 CONCLUSION: Using chronic myeloid leukemia as a model, we show that PgP-mediated resistance to imatinib and anthracyclines can be durably reversed by nonviral, transposon-based knockdown of PgP in malignant cells. Anthracyclines 108-122 ATP binding cassette subfamily B member 1 Homo sapiens 190-193 15703814-10 2005 Interestingly, we found that patients who were on a chemotherapy regime which contained an anthracycline (a Pgp substrate) and subsequently developed recurrence, had a higher YB-1 score compared to patients on the Cyclophosphamide/Methotrexate/5-Fluorouracil regime (P=0.024). Anthracyclines 91-104 ATP binding cassette subfamily B member 1 Homo sapiens 108-111 15457126-1 2004 The expression of P-glycoprotein (P-gp) has been demonstrated to confer resistance to several anticancer drugs, including anthracyclines, taxanes and vinca alkaloids. Anthracyclines 122-136 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 15457126-1 2004 The expression of P-glycoprotein (P-gp) has been demonstrated to confer resistance to several anticancer drugs, including anthracyclines, taxanes and vinca alkaloids. Anthracyclines 122-136 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 14499178-11 2003 These results suggest that N-methylation of anthracyclines circumvents resistance by diminishing drug transport by P-gp in MDR-positive cells. Anthracyclines 44-58 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 12410571-2 2002 Expression of a multidrug resistance gene (mdr1) that codes for 170 Kd transmembrane glycoprotein is responsible for conferring resistance to malignant cells to anthracyclines. Anthracyclines 161-175 ATP binding cassette subfamily B member 1 Homo sapiens 43-47 12914384-9 2003 MRP2 (multi-drug resistance associated protein) and MDR1 (multi-drug resistance gene) are involved in irinotecan as well as anthracyclines transport. Anthracyclines 124-138 ATP binding cassette subfamily B member 1 Homo sapiens 52-56 12516967-1 2002 Human multidrug resistance protein 1 (MRP1) confers resistance to the Vinca alkaloids, the anthracyclines, and the epipodophyllotoxins. Anthracyclines 91-105 ATP binding cassette subfamily B member 1 Homo sapiens 6-36 12516967-1 2002 Human multidrug resistance protein 1 (MRP1) confers resistance to the Vinca alkaloids, the anthracyclines, and the epipodophyllotoxins. Anthracyclines 91-105 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 12542697-9 2003 In addition these values were compared with those determined previously for the P-gp-mediated efflux of anthracycline. Anthracyclines 104-117 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 12542697-10 2003 Our conclusion is that the compounds of these two classes of molecules, anthracyclines and rhodamines, are substrates of P-gp and that their pumping rates at limiting low substrate concentration are similar. Anthracyclines 72-86 ATP binding cassette subfamily B member 1 Homo sapiens 121-125 11850258-2 2002 Treatment of tumor cells with chemotherapeutic agents such as anthracyclines, epipodophyllotoxins, and Vinca alkaloids results in induction of P-gp expression. Anthracyclines 62-76 ATP binding cassette subfamily B member 1 Homo sapiens 143-147 12138343-1 2002 P-glycoprotein (P-gp) transports a wide range of structurally unrelated drugs, such as HIV protease inhibitors (PIs) and cytotoxic compounds such as anthracyclines. Anthracyclines 149-163 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 12138343-1 2002 P-glycoprotein (P-gp) transports a wide range of structurally unrelated drugs, such as HIV protease inhibitors (PIs) and cytotoxic compounds such as anthracyclines. Anthracyclines 149-163 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 11986786-2 2002 Anthracyclines interfere with topoisomerase II, intercalate DNA and are substrates for P-glycoprotein and multidrug resistance-associated protein 1. Anthracyclines 0-14 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 11996888-4 2002 We measured the kinetics of active efflux of seven new anthracycline derivatives in P-gp-expressing K562/ADR cells and in MRP1-expressing GLC4/ADR cells. Anthracyclines 55-68 ATP binding cassette subfamily B member 1 Homo sapiens 84-88 11062698-2 2000 At present, an MDR-1 product, the P-170 glycoprotein, is the best known of the P-170 family and is involved in resistance to natural product-based chemotherapeutics, including taxanes, anthracyclines, vinca alkaloids, podophyllotoxins and camptothecins. Anthracyclines 185-199 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 11719356-1 2001 Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations. Anthracyclines 79-93 ATP binding cassette subfamily B member 1 Homo sapiens 30-44 11719356-1 2001 Cyclosporine A (CsA) inhibits P-glycoprotein (Pgp)-mediated cellular export of anthracyclines at clinically achievable concentrations. Anthracyclines 79-93 ATP binding cassette subfamily B member 1 Homo sapiens 46-49 11585053-3 2001 Thus, both P-gp and MRP1 proteins are able to transport anthracycline but the role of chirality has not, up to now, been addressed. Anthracyclines 56-69 ATP binding cassette subfamily B member 1 Homo sapiens 11-15 11552980-2 2001 Overexpression of the multidrug resistance (MDR-1) gene and its product, P-glycoprotein (P-gp), is associated with cellular resistance to drugs, such as anthracyclines and vinca alkaloids. Anthracyclines 153-167 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 11552980-2 2001 Overexpression of the multidrug resistance (MDR-1) gene and its product, P-glycoprotein (P-gp), is associated with cellular resistance to drugs, such as anthracyclines and vinca alkaloids. Anthracyclines 153-167 ATP binding cassette subfamily B member 1 Homo sapiens 73-87 11552980-2 2001 Overexpression of the multidrug resistance (MDR-1) gene and its product, P-glycoprotein (P-gp), is associated with cellular resistance to drugs, such as anthracyclines and vinca alkaloids. Anthracyclines 153-167 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 11391630-13 2001 Tumors of 27 anthracycline-treated patients had comparable MDR1/P-Gp mRNA expression levels (mean 5.4 x 10(-2)). Anthracyclines 13-26 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 11278596-0 2001 Identification of an amino acid residue in multidrug resistance protein 1 critical for conferring resistance to anthracyclines. Anthracyclines 112-126 ATP binding cassette subfamily B member 1 Homo sapiens 43-73 11791127-0 2001 Resistant mechanisms of anthracyclines--pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues. Anthracyclines 24-38 ATP binding cassette subfamily B member 1 Homo sapiens 83-97 11791127-2 2001 After much research on anthracycline-resistance, this P-gp was finally characterized as a multidrug-resistant protein coded by the mdr1 gene. Anthracyclines 23-36 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 11791127-2 2001 After much research on anthracycline-resistance, this P-gp was finally characterized as a multidrug-resistant protein coded by the mdr1 gene. Anthracyclines 23-36 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 11172692-7 2001 Our recent studies have shown that whereas the P-gp- and MRP1-mediated efflux of different anthracycline-based drugs may not differ considerably, their kinetics of uptake do. Anthracyclines 91-104 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 11399635-1 2001 We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo diagnosed acute myeloid leukaemia (AML) and the relationship between presence of P-gp in leukaemic cells and efficacy, as remission induction and survival rate, of two different anthracyclines, daunorubicin (DNR) and idarubicin (IDR). Anthracyclines 260-274 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 11187897-1 2000 Overexpression of P-glycoprotein (P-gp) in cancer cells reduces intracellular accumulation of various anticancer drugs including anthracyclines and vinca alkaloids. Anthracyclines 129-143 ATP binding cassette subfamily B member 1 Homo sapiens 18-32 11187897-1 2000 Overexpression of P-glycoprotein (P-gp) in cancer cells reduces intracellular accumulation of various anticancer drugs including anthracyclines and vinca alkaloids. Anthracyclines 129-143 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 11869937-2 2002 The principal aim was to define the maximum tolerated dose (MTD) of IDR, which is reported to be a less MDR1-sensitive anthracycline. Anthracyclines 119-132 ATP binding cassette subfamily B member 1 Homo sapiens 104-108 11911247-1 2001 BACKGROUND: MDR1 or MRP1 drug resistance mechanisms seriously limit the efficacy of anthracyclines such as doxorubicin, in the treatment of acute myeloid leukemia (AML). Anthracyclines 84-98 ATP binding cassette subfamily B member 1 Homo sapiens 12-16 11911247-2 2001 Our studies indicated that reducing basicity, increasing steric hindrance at C-4", and/or lipophilicity may help circumvent P-glycoprotein (P-gp)-mediated anthracycline efflux and thus increase drug retention in MDR-positive cells. Anthracyclines 155-168 ATP binding cassette subfamily B member 1 Homo sapiens 124-138 11911247-2 2001 Our studies indicated that reducing basicity, increasing steric hindrance at C-4", and/or lipophilicity may help circumvent P-glycoprotein (P-gp)-mediated anthracycline efflux and thus increase drug retention in MDR-positive cells. Anthracyclines 155-168 ATP binding cassette subfamily B member 1 Homo sapiens 140-144 11429411-1 2001 Murine multidrug resistance protein 1 (mrp1), differs from its human ortholog (MRP1) in that it fails to confer anthracycline resistance and transports the MRP1 substrate, 17beta-estradiol 17-(beta-d-glucuronide) (E(2)17betaG), very poorly. Anthracyclines 112-125 ATP binding cassette subfamily B member 1 Homo sapiens 7-37 11429411-1 2001 Murine multidrug resistance protein 1 (mrp1), differs from its human ortholog (MRP1) in that it fails to confer anthracycline resistance and transports the MRP1 substrate, 17beta-estradiol 17-(beta-d-glucuronide) (E(2)17betaG), very poorly. Anthracyclines 112-125 ATP binding cassette subfamily B member 1 Homo sapiens 39-43 11248673-0 2001 P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Anthracyclines 39-53 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 11475537-7 2000 Experimental studies have demonstrated that certain structural modifications of anthracyclines confer the ability to escape Pgp transport. Anthracyclines 80-94 ATP binding cassette subfamily B member 1 Homo sapiens 124-127 10651800-0 2000 The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells. Anthracyclines 63-76 ATP binding cassette subfamily B member 1 Homo sapiens 39-53 10792272-1 2000 We analysed the expression of three drug transporter proteins [p-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP1)] involved in anthracycline resistance that are frequently overexpressed in poor-risk adult acute non-lymphocytic leukaemia (ANLL), in 23 acute promyelocytic leukaemia (APL) patients at onset managed at a single institution. Anthracyclines 187-200 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 10792272-1 2000 We analysed the expression of three drug transporter proteins [p-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP1)] involved in anthracycline resistance that are frequently overexpressed in poor-risk adult acute non-lymphocytic leukaemia (ANLL), in 23 acute promyelocytic leukaemia (APL) patients at onset managed at a single institution. Anthracyclines 187-200 ATP binding cassette subfamily B member 1 Homo sapiens 79-82 10792272-8 2000 These results are consistent with the view that low PGP, LRP and MRP1 expression and the absence of defects in intracellular drug accumulation may account for the peculiarly high sensitivity of APLs to anthracycline. Anthracyclines 202-215 ATP binding cassette subfamily B member 1 Homo sapiens 52-55 10498614-1 1999 Expression of the multidrug resistance (MDR) mechanisms P-glycoprotein (Pgp) and MDR-related protein (MRP) decrease cellular retention and consequently cytotoxicity of anthracyclines. Anthracyclines 168-182 ATP binding cassette subfamily B member 1 Homo sapiens 56-70 11127949-1 2000 Annamycin is a highly lipophilic anthracycline with the ability to bypass the MDR-1 mechanism of cellular drug resistance. Anthracyclines 33-46 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 10655559-1 2000 BACKGROUND: Anthracycline resistance is known to be mediated by P-glycoprotein (P-gp) or multidrug-resistance related protein (MRP) as well as intracellular sequestration of drugs. Anthracyclines 12-25 ATP binding cassette subfamily B member 1 Homo sapiens 64-78 10655559-1 2000 BACKGROUND: Anthracycline resistance is known to be mediated by P-glycoprotein (P-gp) or multidrug-resistance related protein (MRP) as well as intracellular sequestration of drugs. Anthracyclines 12-25 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 27420927-1 2000 We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo diagnosed acute myeloid leukaemia (AML) and the relationship between presence of P-gp in leukaemic cells and efficacy, as remission induction and survival rate, of two different anthracyclines, daunorubicin (DNR) and idarubicin (IDR). Anthracyclines 260-274 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 10498614-1 1999 Expression of the multidrug resistance (MDR) mechanisms P-glycoprotein (Pgp) and MDR-related protein (MRP) decrease cellular retention and consequently cytotoxicity of anthracyclines. Anthracyclines 168-182 ATP binding cassette subfamily B member 1 Homo sapiens 72-75 10544072-3 1999 Several factors like P-glycoprotein mediated drug resistance (MDR-1 or MRP), glutathione or amplification of topoisomerase II have been found to be involved in anthracycline resistance. Anthracyclines 160-173 ATP binding cassette subfamily B member 1 Homo sapiens 62-67 10364203-7 1999 Different conformational states were adopted by P-glycoprotein upon the addition of the anthracycline derivatives in the absence and presence of MgATP or MgATPgammaS. Anthracyclines 88-101 ATP binding cassette subfamily B member 1 Homo sapiens 48-62 10418960-0 1999 Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue. Anthracyclines 63-77 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 10418960-2 1999 The effect on P-gp-mediated transport of anthracyclines of cell irradiation in the presence of 2,2-diphenyl-5-[N-1-(o-azidophenyl)ethylamino]valeronitrile (VP*), a photoactivable analogue of verapamil was studied in viable K562/ADR cells. Anthracyclines 41-55 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 10418960-9 1999 With those used in that study, after the photoirradiation of K562 ADR cells in the presence of VP* and anthracycline, P-gp has retained 50 +/- 5% of its functionality. Anthracyclines 103-116 ATP binding cassette subfamily B member 1 Homo sapiens 118-122 10395948-0 1999 Correlation between the kinetics of anthracycline uptake and the resistance factor in cancer cells expressing the multidrug resistance protein or the P-glycoprotein. Anthracyclines 36-49 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 10395948-7 1999 In this work, the kinetics of drug uptake and the kinetics of active efflux of several anthracycline derivatives in both Pgp expressing K562/Adr cells and MRP1 expressing GLC4/Adr cells was determined. Anthracyclines 87-100 ATP binding cassette subfamily B member 1 Homo sapiens 121-124 10361105-7 1999 In Pgp-negative blasts, all four anthracyclines and AraC significantly increased Pgp expression (P =.01) and Pgp function (P =.03). Anthracyclines 33-47 ATP binding cassette subfamily B member 1 Homo sapiens 3-6 10361105-7 1999 In Pgp-negative blasts, all four anthracyclines and AraC significantly increased Pgp expression (P =.01) and Pgp function (P =.03). Anthracyclines 33-47 ATP binding cassette subfamily B member 1 Homo sapiens 81-84 10361105-7 1999 In Pgp-negative blasts, all four anthracyclines and AraC significantly increased Pgp expression (P =.01) and Pgp function (P =.03). Anthracyclines 33-47 ATP binding cassette subfamily B member 1 Homo sapiens 81-84 10070877-0 1999 Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Anthracyclines 37-50 ATP binding cassette subfamily B member 1 Homo sapiens 13-17 10092063-1 1999 P-glycoprotein (Pgp)-associated multidrug resistance (MDR) is related to intrinsic and acquired cross resistance to anthracyclines, vinca alkaloids, and other antineoplastic antibiotics. Anthracyclines 116-130 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 10092063-1 1999 P-glycoprotein (Pgp)-associated multidrug resistance (MDR) is related to intrinsic and acquired cross resistance to anthracyclines, vinca alkaloids, and other antineoplastic antibiotics. Anthracyclines 116-130 ATP binding cassette subfamily B member 1 Homo sapiens 16-19 10342576-1 1999 Ways of restoring an altered drug sensitivity in P-170 glycoprotein (MDR1) positive leukemias are being actively sought for, mostly using MDRI negative regulators together with the MDR1-sensitive anthracycline-type drugs daunorubicin and mitoxantrone. Anthracyclines 196-209 ATP binding cassette subfamily B member 1 Homo sapiens 69-73 10342576-1 1999 Ways of restoring an altered drug sensitivity in P-170 glycoprotein (MDR1) positive leukemias are being actively sought for, mostly using MDRI negative regulators together with the MDR1-sensitive anthracycline-type drugs daunorubicin and mitoxantrone. Anthracyclines 196-209 ATP binding cassette subfamily B member 1 Homo sapiens 181-185 10070877-11 1999 For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. Anthracyclines 14-28 ATP binding cassette subfamily B member 1 Homo sapiens 46-50 10070877-13 1999 This study demonstrates that MDR1 expression can be induced by analogues of anthracyclines not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period. Anthracyclines 76-90 ATP binding cassette subfamily B member 1 Homo sapiens 29-33 10500777-8 1999 The fact that we obtained higher indications of resistance reversal using the MTT assay along with finding P-gp expression and function in patients sensitive to the anthracyclines, suggests studies of P-gp should be teemed with chemosensitivity testing to identify specific patients who will benefit. Anthracyclines 165-179 ATP binding cassette subfamily B member 1 Homo sapiens 201-205 9744556-0 1998 Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids. Anthracyclines 92-106 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 10500807-0 1999 Apoptosis by anthracyclines at therapeutic concentrations in MDR1+ human leukemic cells. Anthracyclines 13-27 ATP binding cassette subfamily B member 1 Homo sapiens 61-65 10500774-2 1999 Several large cohorts of newly diagnosed AML patients treated with a classical anthracycline + standard doses of cytosine arabinoside were tested for the prognosis value of MDR1 phenotype, and demonstrated an high correlation between a significant increase of MDR1 gene expression and treatment failure (or, better, drug resistance). Anthracyclines 79-92 ATP binding cassette subfamily B member 1 Homo sapiens 260-264 10500774-3 1999 This P-gp(+) drug resistance could be due either to a particular phenotype of bad prognosis AML, as it is suggested by the association of myelodysplasia, complex karyotype and advanced age with MDR1 phenotype, or due primarily to the active efflux of anthracyclines and VP16 in P-gp(+) leukemic cells. Anthracyclines 251-265 ATP binding cassette subfamily B member 1 Homo sapiens 5-9 10500774-3 1999 This P-gp(+) drug resistance could be due either to a particular phenotype of bad prognosis AML, as it is suggested by the association of myelodysplasia, complex karyotype and advanced age with MDR1 phenotype, or due primarily to the active efflux of anthracyclines and VP16 in P-gp(+) leukemic cells. Anthracyclines 251-265 ATP binding cassette subfamily B member 1 Homo sapiens 278-282 10500774-4 1999 Several observations tend to confirm the functional role of the P-gp in clinical drug resistance; (i) using multivariate analysis, MDR1 phenotype appears to be an independent variable, as potent (or higher) as karyotype and age for predicting in vivo drug resistance; (ii) the prognostic value is limited to the CD34(+)/P-gp(+) phenotype, wich is linked to a functional P-gp; (iii) the in vitro sensitivity to anthracyclines and VP16 is highly correlated with P-gp expression. Anthracyclines 410-424 ATP binding cassette subfamily B member 1 Homo sapiens 64-68 10500774-4 1999 Several observations tend to confirm the functional role of the P-gp in clinical drug resistance; (i) using multivariate analysis, MDR1 phenotype appears to be an independent variable, as potent (or higher) as karyotype and age for predicting in vivo drug resistance; (ii) the prognostic value is limited to the CD34(+)/P-gp(+) phenotype, wich is linked to a functional P-gp; (iii) the in vitro sensitivity to anthracyclines and VP16 is highly correlated with P-gp expression. Anthracyclines 410-424 ATP binding cassette subfamily B member 1 Homo sapiens 131-135 10500777-0 1999 Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML. Anthracyclines 82-96 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 10500777-6 1999 However it was possible to identify individual patients whose cells exhibited P-gp expression and function teamed with in vitro resistance to, and modification of, the anthracyclines. Anthracyclines 168-182 ATP binding cassette subfamily B member 1 Homo sapiens 78-82 10500777-8 1999 The fact that we obtained higher indications of resistance reversal using the MTT assay along with finding P-gp expression and function in patients sensitive to the anthracyclines, suggests studies of P-gp should be teemed with chemosensitivity testing to identify specific patients who will benefit. Anthracyclines 165-179 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 9846505-0 1998 Antitumor spectra of anthracyclines against gastric cancer tissues obtained from surgical specimens with reference to P-glycoprotein expression. Anthracyclines 21-35 ATP binding cassette subfamily B member 1 Homo sapiens 118-132 9846505-1 1998 BACKGROUND AND OBJECTIVES: Although the mechanism of P-glycoprotein (Pgp)-related resistance of doxorubicin is known, it has not been clarified for other anthracycline derivatives. Anthracyclines 154-167 ATP binding cassette subfamily B member 1 Homo sapiens 53-67 9846505-1 1998 BACKGROUND AND OBJECTIVES: Although the mechanism of P-glycoprotein (Pgp)-related resistance of doxorubicin is known, it has not been clarified for other anthracycline derivatives. Anthracyclines 154-167 ATP binding cassette subfamily B member 1 Homo sapiens 69-72 9846505-2 1998 We have examined the chemosensitivity of gastric cancer tissues to three anthracyclines in relation to Pgp expression. Anthracyclines 73-87 ATP binding cassette subfamily B member 1 Homo sapiens 103-106 9806185-0 1998 The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Anthracyclines 64-77 ATP binding cassette subfamily B member 1 Homo sapiens 32-38 9806185-2 1998 and to correlate gp-170 with the natural and acquired drug resistance of these cell lines to anthracyclines. Anthracyclines 93-107 ATP binding cassette subfamily B member 1 Homo sapiens 17-23 9744556-1 1998 Cells that overexpress the mdr 1 gene have decreased steady-state accumulation and increased efflux of many anticancer drugs including anthracyclines and vinca alkaloids. Anthracyclines 135-149 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 9744556-6 1998 It has been shown that the P-glycoprotein-mediated efflux of these three anthracyclines can be inhibited by vinca alkaloids derivatives. Anthracyclines 73-87 ATP binding cassette subfamily B member 1 Homo sapiens 27-41 9626462-1 1998 The purpose of this study is to evaluate whether metastatic breast cancer that has progressed on an anthracycline-containing drug regimen will subsequently respond to that identical regimen if dexverapamil, a modulator of P-glycoprotein-mediated drug resistance, is given concomitantly. Anthracyclines 100-113 ATP binding cassette subfamily B member 1 Homo sapiens 222-236 9615748-10 1998 Pgp was expressed in 23.5% (12/51) specimens and the efficacy of anthracyclines was reduced in Pgp-positive breast cancer tissues, although this reduction was low in THP with a statistically significant difference when comparing with DXR and EPIR. Anthracyclines 65-79 ATP binding cassette subfamily B member 1 Homo sapiens 95-98 9602329-1 1998 AIMS: Most chemotherapeutic regimens used against gastric carcinoma include anthracyclines whose effectiveness can be impaired by the presence of P-glycoprotein. Anthracyclines 76-90 ATP binding cassette subfamily B member 1 Homo sapiens 146-160 9520154-0 1998 Differential resistance to anthracyclines in P-glycoprotein-expressing human hepatoma cells. Anthracyclines 27-41 ATP binding cassette subfamily B member 1 Homo sapiens 45-59 9570481-3 1998 The kinetics of P-glycoprotein-mediated efflux of various anthracycline derivatives was measured in multidrug-resistant (MDR) K562 cells in the presence of verapamil. Anthracyclines 58-71 ATP binding cassette subfamily B member 1 Homo sapiens 16-30 9570481-5 1998 Our data show (1) that verapamil is unable to completely block the P-glycoprotein-mediated efflux of anthracyclines and that 10% of its functionality remains even with high verapamil concentrations, (2) that the ability of verapamil to restore intracellular accumulation of anthracyclines in MDR cells depends on the kinetics of their uptake. Anthracyclines 101-115 ATP binding cassette subfamily B member 1 Homo sapiens 67-81 9523723-8 1998 Our data show that (a) P-glycoprotein and MRP transporter efficiencies to wash out Tc-MIBI are similar, in spite of a different suspected mechanism of its transport and (b) that both transporters are less efficient to pump Tc-MIBI than to pump anthracyclines (the ka parameter is about 100-times lower for TC-MIBI than for anthracycline). Anthracyclines 244-258 ATP binding cassette subfamily B member 1 Homo sapiens 23-37 9523723-8 1998 Our data show that (a) P-glycoprotein and MRP transporter efficiencies to wash out Tc-MIBI are similar, in spite of a different suspected mechanism of its transport and (b) that both transporters are less efficient to pump Tc-MIBI than to pump anthracyclines (the ka parameter is about 100-times lower for TC-MIBI than for anthracycline). Anthracyclines 244-257 ATP binding cassette subfamily B member 1 Homo sapiens 23-37 9443942-4 1998 We have studied the transport kinetics of a series of anthracyclines in MRP and Pgp that overexpress tumor cell lines to obtain information on the substrate specificity of these proteins. Anthracyclines 54-68 ATP binding cassette subfamily B member 1 Homo sapiens 80-83 9443942-8 1998 Two anthracyclines, the doxorubicin derivative pirarubicin and 2"-bromo-4"-epi-DNR seemed to have a slightly higher Ka value for Pgp than for MRP. Anthracyclines 4-18 ATP binding cassette subfamily B member 1 Homo sapiens 129-132 9443942-10 1998 Determination of the Hill coefficient (nH) of the MRP-mediated efflux gave most values close to 2, which suggests cooperativity of the transport of anthracyclines as reported before for Pgp. Anthracyclines 148-162 ATP binding cassette subfamily B member 1 Homo sapiens 186-189 9443942-11 1998 In conclusion, the transport kinetics of anthracyclines by MRP and Pgp are very similar. Anthracyclines 41-55 ATP binding cassette subfamily B member 1 Homo sapiens 67-70 10021886-8 1998 Pgp is responsible for cell resistance to cytotoxic compounds of natural origin, such as anthracyclines, vinca alkaloids, epipodophyllotoxins, taxanes, colchicine and amsacrine. Anthracyclines 89-103 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 9687882-3 1998 Cell lines expressing mdr1 exhibit resistance to several structurally unrelated lipophilic drugs, such as anthracyclines, vinca alkaloids, and epopodophyllotoxins. Anthracyclines 106-120 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 9481450-4 1997 One of the major problems with anthracycline therapy is the development of resistance which may be mediated by p-glycoprotein or by other mechanisms. Anthracyclines 31-44 ATP binding cassette subfamily B member 1 Homo sapiens 111-125 8956784-0 1996 Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. Anthracyclines 102-116 ATP binding cassette subfamily B member 1 Homo sapiens 29-43 9029024-0 1997 A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Anthracyclines 105-118 ATP binding cassette subfamily B member 1 Homo sapiens 35-39 9393602-1 1997 Multidrug resistance (MDR) mediated by the drug efflux pump P-glycoprotein (Pgp), may cause remission failure and relapse in patients with acute myeloid leukaemia (AML) by extruding cytotoxic agents such as anthracyclines from leukaemic cells thus allowing them to survive. Anthracyclines 207-221 ATP binding cassette subfamily B member 1 Homo sapiens 60-74 9393602-1 1997 Multidrug resistance (MDR) mediated by the drug efflux pump P-glycoprotein (Pgp), may cause remission failure and relapse in patients with acute myeloid leukaemia (AML) by extruding cytotoxic agents such as anthracyclines from leukaemic cells thus allowing them to survive. Anthracyclines 207-221 ATP binding cassette subfamily B member 1 Homo sapiens 76-79 9252419-2 1997 This study reports on the localization of the binding site of P-glycoprotein for iodomycin, the Bolton-Hunter derivative of the anthracycline daunomycin. Anthracyclines 128-141 ATP binding cassette subfamily B member 1 Homo sapiens 62-76 9275001-4 1997 P-glycoprotein (Pgp)-mediated multidrug resistance, the most studied form of anthracycline resistance, can be inhibited by a variety of chemicals. Anthracyclines 77-90 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 9275001-4 1997 P-glycoprotein (Pgp)-mediated multidrug resistance, the most studied form of anthracycline resistance, can be inhibited by a variety of chemicals. Anthracyclines 77-90 ATP binding cassette subfamily B member 1 Homo sapiens 16-19 9275001-8 1997 Correlating overexpression of the MDR1 gene in human tumor samples with treatment failure has not proved straightforward, and further studies are needed to clarify the contribution of multidrug resistance mechanisms to clinical anthracycline resistance. Anthracyclines 228-241 ATP binding cassette subfamily B member 1 Homo sapiens 34-38 9044851-1 1997 P-glycoprotein expression in lymphoid malignancies has the potential to compromise the efficacy of many therapeutic regimens using anthracyclines, glucocorticoids, and Vinca alkaloids. Anthracyclines 131-145 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8956784-2 1996 The most effective single agents in treatment of primary liver carcinoma belong to the anthracycline family, yet several anthracyclines are known to be substrates for Pgp. Anthracyclines 87-100 ATP binding cassette subfamily B member 1 Homo sapiens 167-170 8956784-2 1996 The most effective single agents in treatment of primary liver carcinoma belong to the anthracycline family, yet several anthracyclines are known to be substrates for Pgp. Anthracyclines 121-135 ATP binding cassette subfamily B member 1 Homo sapiens 167-170 8702500-5 1996 We find that an erg6 mutation, which blocks the final synthetic step of the membrane sterol ergosterol, renders yeast sensitive to anthracyclines and dactinomycin, clinically relevant Pgp substrates. Anthracyclines 131-145 ATP binding cassette subfamily B member 1 Homo sapiens 184-187 8704189-2 1996 P-glycoprotein (P-gp) functions as a membrane-associated drug efflux pump whose increased expression results in resistance to anthracyclines, epipodophyllotoxins, vinca alkaloids, and some alkylating agents. Anthracyclines 126-140 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 8694845-7 1996 Our data provide the first evidence that the binding of a verapamil analogue to P-gp is not sufficient to completely inhibit the efflux of this anthracycline. Anthracyclines 144-157 ATP binding cassette subfamily B member 1 Homo sapiens 80-84 8695811-1 1996 A major factor in limiting the efficacy of anthracyclines is overexpression of the MDR1-encoded p-glycoprotein (p-gp). Anthracyclines 43-57 ATP binding cassette subfamily B member 1 Homo sapiens 83-87 8695811-1 1996 A major factor in limiting the efficacy of anthracyclines is overexpression of the MDR1-encoded p-glycoprotein (p-gp). Anthracyclines 43-57 ATP binding cassette subfamily B member 1 Homo sapiens 96-110 8695811-1 1996 A major factor in limiting the efficacy of anthracyclines is overexpression of the MDR1-encoded p-glycoprotein (p-gp). Anthracyclines 43-57 ATP binding cassette subfamily B member 1 Homo sapiens 112-116 8704189-2 1996 P-glycoprotein (P-gp) functions as a membrane-associated drug efflux pump whose increased expression results in resistance to anthracyclines, epipodophyllotoxins, vinca alkaloids, and some alkylating agents. Anthracyclines 126-140 ATP binding cassette subfamily B member 1 Homo sapiens 16-20 9816222-0 1996 Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Anthracyclines 70-84 ATP binding cassette subfamily B member 1 Homo sapiens 51-55 9816243-1 1996 The multiple drug resistance (MDR) gene P-glycoprotein product is a transmembrane efflux pump that prevents toxicity of a variety of chemotherapeutic agents, including the anthracyclines, Vinca alkaloids, podophyllins, and taxol. Anthracyclines 172-186 ATP binding cassette subfamily B member 1 Homo sapiens 40-54 7734315-0 1995 Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Anthracyclines 42-56 ATP binding cassette subfamily B member 1 Homo sapiens 23-27 8862011-1 1996 We investigated the expression of P-glycoprotein (P-gp) in 50 adults with de novo acute myeloid leukemia (AML) at the initial diagnosis in order to further define the relationship between the presence of P-gp on leukemic cells and the efficacy of two different anthracycline drugs, Daunorubicin (DNR) and Idarubicin (IRR), in terms of remission, induction and survival. Anthracyclines 261-274 ATP binding cassette subfamily B member 1 Homo sapiens 34-48 8669809-2 1995 Resistance to several cytotoxic agents (MultiDrug Resistance MDR), including anthracyclines, vinca alkaloids and epipodophylline derivatives can occur in human osteosarcoma (OS) cells, detected by the overexpression of a 170 kD glycoprotein (p170), as a result of increased expression of the MDR gene (mdr1). Anthracyclines 77-91 ATP binding cassette subfamily B member 1 Homo sapiens 302-306 7794759-1 1995 The MDR1 gene product, P-glycoprotein, functions as a transmembrane efflux pump for certain cytotoxic agents including anthracyclines. Anthracyclines 119-133 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 7794759-1 1995 The MDR1 gene product, P-glycoprotein, functions as a transmembrane efflux pump for certain cytotoxic agents including anthracyclines. Anthracyclines 119-133 ATP binding cassette subfamily B member 1 Homo sapiens 23-37 7794759-8 1995 We conclude that low or absent expression of MDR1 in APL cells may contribute to the efficacy of anthracyclines in the treatment of APL. Anthracyclines 97-111 ATP binding cassette subfamily B member 1 Homo sapiens 45-49 7575681-0 1995 The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Anthracyclines 106-120 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 7575681-8 1995 It was shown that the passive drug permeation coefficient as well as the drug pumping rate of P-gp increased with increasing lipophilicity in this series of anthracyclines. Anthracyclines 157-171 ATP binding cassette subfamily B member 1 Homo sapiens 94-98 7575681-12 1995 In conclusion, for several anthracyclines the activity of P-gp leads to a similar relative decrease in the cytosolic free drug concentration; consequently, the reported lower resistance factor of IDA compared to that of DNR is not due to the inability of P-gp to export IDA from cells. Anthracyclines 27-41 ATP binding cassette subfamily B member 1 Homo sapiens 58-62 7670142-1 1995 Multidrug resistance (MDR) is associated with poor prognosis in leukemia, and anthracyclines, which are used in the treatment of leukemia, are associated with the expression of P-glycoprotein and the development of MDR. Anthracyclines 78-92 ATP binding cassette subfamily B member 1 Homo sapiens 177-191 7670142-3 1995 The P-glycoprotein expressing, multidrug resistant sublines developed to daunorubicin (K/DNR), doxorubicin (K/DOX) and epirubicin (K/EPR) were cross-resistant to the other anthracyclines and to vinblastine, taxol, colchicine and actinomycin D, but were not resistant to idarubicin or etoposide. Anthracyclines 172-186 ATP binding cassette subfamily B member 1 Homo sapiens 4-18 7645952-2 1995 P-gp acts as an ATP-dependent efflux pump causing a decreased intracellular accumulation of structurally unrelated natural anticancer agents such as anthracyclines. Anthracyclines 149-163 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 7734315-2 1995 The induction of mdr1 RNA expression by three anthracyclines, (doxorubicin, daunorubicin, epirubicin), VP-16 and two vinca alkaloids (vincristine, vinblastine) was semiquantitatively assessed by scanning Northern blots on a phosphorimager. Anthracyclines 46-60 ATP binding cassette subfamily B member 1 Homo sapiens 17-21 7912544-0 1994 Modification by brefeldin A, bafilomycin A1 and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R. Anthracyclines 152-166 ATP binding cassette subfamily B member 1 Homo sapiens 178-192 7540457-1 1995 Expression of MDR1 is a well-characterized mechanism leading to resistance of tumor cells to drugs like vinca-alkaloids, anthracyclines, and epipodophyllotoxins. Anthracyclines 121-135 ATP binding cassette subfamily B member 1 Homo sapiens 14-18 7579508-3 1995 Premenopausal status appeared to correlate with increased p-glycoprotein expression, but this probably reflects patient selection as premenopausal patients had higher prior exposure to anthracyclines and were more likely to have received chemotherapy as initial treatment. Anthracyclines 185-199 ATP binding cassette subfamily B member 1 Homo sapiens 58-72 7805856-0 1994 P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells. Anthracyclines 60-73 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 7727862-2 1994 The most studied one is the glycoprotein coded by the mdr1 gene, which is involved in the efflux of numerous compounds of natural origin (anthracyclines, podophyllotoxins...) thus decreasing the intracellular concentration of such drugs. Anthracyclines 138-152 ATP binding cassette subfamily B member 1 Homo sapiens 54-58 7702633-0 1995 Characterization of an anthracycline-resistant human promyelocyte leukemia (HL-60) cell line with an elevated MDR-1 gene expression. Anthracyclines 23-36 ATP binding cassette subfamily B member 1 Homo sapiens 110-115 7702633-4 1995 We have isolated, by drug selection, an anthracycline-resistant HL-60 cell line that, in comparison to parental drug sensitive cells, exhibits a multidrug resistant phenotype including diminished intracellular drug retention, cross-resistance to multiple cytotoxic drugs, increased expression of a monoclonal antibody C219-reactive 180 kDa P-glycoprotein detected by Western blot analysis as well as increased expression of MDR-1 mRNA as determined by Northern blot and solution hybridization/RNAse protection analyses. Anthracyclines 40-53 ATP binding cassette subfamily B member 1 Homo sapiens 340-354 7702633-4 1995 We have isolated, by drug selection, an anthracycline-resistant HL-60 cell line that, in comparison to parental drug sensitive cells, exhibits a multidrug resistant phenotype including diminished intracellular drug retention, cross-resistance to multiple cytotoxic drugs, increased expression of a monoclonal antibody C219-reactive 180 kDa P-glycoprotein detected by Western blot analysis as well as increased expression of MDR-1 mRNA as determined by Northern blot and solution hybridization/RNAse protection analyses. Anthracyclines 40-53 ATP binding cassette subfamily B member 1 Homo sapiens 424-429 7702633-5 1995 Evidence is presented that the anthracycline-resistant HL-60 cells have amplified the MDR-1 gene. Anthracyclines 31-44 ATP binding cassette subfamily B member 1 Homo sapiens 86-91 7977168-2 1994 The increased uptake of liposomes by colon adenocarcinoma cell lines may enable DaunoXome to circumvent the p-glycoprotein-mediated anthracycline resistance of colon cancer cells. Anthracyclines 132-145 ATP binding cassette subfamily B member 1 Homo sapiens 108-122 7896208-1 1994 BACKGROUND: Overexpression of the mdr-1 gene that codes for a 170 Kd transmembrane glycoprotein (P170) is a factor responsible for decreased cell sensitivity to anthracyclines and other drugs, and is related to treatment failure in acute leukemia and other tumors. Anthracyclines 161-175 ATP binding cassette subfamily B member 1 Homo sapiens 34-39 7518390-10 1994 From our data showing that lipophilic neutral complexes, formed between carboxylic ionophores and metal ions, are both able to inhibit the P-glycoprotein-mediated efflux of anthracycline we can infer that the lipophilicity but not the cationic charge is an important physical property. Anthracyclines 173-186 ATP binding cassette subfamily B member 1 Homo sapiens 139-153 7919456-3 1994 With highly resistant cells expressing high levels of Pgp, one such compound (SDZ 280-125) was shown here to restore both a normal sensitivity to the growth-inhibitory effects of ACD and a normal retention of an anthracycline antibiotic. Anthracyclines 212-225 ATP binding cassette subfamily B member 1 Homo sapiens 54-57 7912754-5 1994 Northern blot analysis of MDR1 and MDR3 gene expression in 32 of the patients gave a similar result: in the analysis of total RNA four of six patients (66%) pretreated with either vinca alkaloids or anthracyclines were MDR1 positive as opposed to 6 of 26 (23%) who had no treatment or treatment without these agents. Anthracyclines 199-213 ATP binding cassette subfamily B member 1 Homo sapiens 26-30 7912754-5 1994 Northern blot analysis of MDR1 and MDR3 gene expression in 32 of the patients gave a similar result: in the analysis of total RNA four of six patients (66%) pretreated with either vinca alkaloids or anthracyclines were MDR1 positive as opposed to 6 of 26 (23%) who had no treatment or treatment without these agents. Anthracyclines 199-213 ATP binding cassette subfamily B member 1 Homo sapiens 219-223 18476229-1 1994 Inhibition of P-glycoprotein-mediated Efflux of Anthracyclines by Ionophores. Anthracyclines 48-62 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 7914378-0 1994 Expression of P-glycoprotein influences resistance against anthracyclines in clinical gastric carcinomas. Anthracyclines 59-73 ATP binding cassette subfamily B member 1 Homo sapiens 14-28 7914378-6 1994 We suggested that P-gp expression is closely related to chemosensitivities of human gastric cancers to anthracyclines. Anthracyclines 103-117 ATP binding cassette subfamily B member 1 Homo sapiens 18-22 7904185-2 1994 The fluorescence emission spectra from anthracycline-treated cells suspended in buffer have been used to follow the P-gp-associated efflux of these drugs in the absence or presence of verapamil. Anthracyclines 39-52 ATP binding cassette subfamily B member 1 Homo sapiens 116-120 7909572-5 1994 The classical MDR phenotype is caused by enhanced cellular drug efflux due to increased activity of a membrane-bound glycoprotein (P-glycoprotein) drug pump, that can pump out anthracyclines, anthracenediones, vinca alkaloids and epipodophyllotoxins, thereby actively lowering the intracellular drug concentrations to sublethal levels. Anthracyclines 176-190 ATP binding cassette subfamily B member 1 Homo sapiens 131-145 18476229-8 1994 We here report that mobile ionophores such as valinomycin, nonactin, nigericin, monensin, calcimycin, lasalocid inhibit the efflux of anthracycline by P-glycoprotein whereas, channel-forming ionophores such as gramicidin do not. Anthracyclines 134-147 ATP binding cassette subfamily B member 1 Homo sapiens 151-165 18476229-9 1994 Cyclosporin which is also a strong Ca(2+) chelating agent also inhibits the P-glycoprotein-mediated efflux of anthracycline. Anthracyclines 110-123 ATP binding cassette subfamily B member 1 Homo sapiens 76-90 7902089-1 1993 In order to address the association of enhanced drug efflux with the multidrug-resistant (MDR) phenotype, we have studied the cellular pharmacokinetics of anthracyclines in the P-glycoprotein (Pgp)-positive MDR cell lines H69/LX4 (human small cell lung cancer) and EMT6/AR1.0 (mouse mammary tumour). Anthracyclines 155-169 ATP binding cassette subfamily B member 1 Homo sapiens 177-191 7902089-1 1993 In order to address the association of enhanced drug efflux with the multidrug-resistant (MDR) phenotype, we have studied the cellular pharmacokinetics of anthracyclines in the P-glycoprotein (Pgp)-positive MDR cell lines H69/LX4 (human small cell lung cancer) and EMT6/AR1.0 (mouse mammary tumour). Anthracyclines 155-169 ATP binding cassette subfamily B member 1 Homo sapiens 193-196 7902089-8 1993 The altered cellular pharmacology in MDR cell lines may provide a rational basis for the use of modified anthracycline analogues (e.g. 9-alkyl and morpholinyl (substituted) and resistance of modifying agent in the treatment of tumours expressing a Pgp-mediated phenotype. Anthracyclines 105-118 ATP binding cassette subfamily B member 1 Homo sapiens 248-251 27463350-4 1991 Two of the 14 patients with anthracycline resistant chronic lymphocytic leukaemia (CLL) expressed P-gp but none of the 26 CLL patients resistant only to chlorambucil expressed it. Anthracyclines 28-41 ATP binding cassette subfamily B member 1 Homo sapiens 98-102 7765326-4 1993 Expression of a glycoprotein (referred to as P-glycoprotein) in the membrane of cells made resistant in vitro to naturally occurring anticancer agents like anthracyclines, Vinca alkaloids and epipodophyllotoxins, has been shown to be responsible for the so-called classical MDR phenotype. Anthracyclines 156-170 ATP binding cassette subfamily B member 1 Homo sapiens 45-59 1394128-1 1992 Anthracycline-resistant HL-60/AR cells and their drug-sensitive HL-60/S counterparts were characterized by karyotypic analysis and examined for the overexpression of DNA and mRNA sequences coding for P-glycoprotein (Pgp). Anthracyclines 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 200-214 1394128-1 1992 Anthracycline-resistant HL-60/AR cells and their drug-sensitive HL-60/S counterparts were characterized by karyotypic analysis and examined for the overexpression of DNA and mRNA sequences coding for P-glycoprotein (Pgp). Anthracyclines 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 216-219 8102639-18 1993 CONCLUSION: High doses of CsA, which achieve blood concentrations capable of reversing P-glycoprotein-mediated anthracycline resistance in vitro, can be incorporated into induction regimens with acceptable nonhematologic toxicity. Anthracyclines 111-124 ATP binding cassette subfamily B member 1 Homo sapiens 87-101 1360820-11 1992 PGP-mediated cellular drug resistance may thus be circumvented in leukemic blasts by application of chemosensitizers or, potentially, alternative anthracyclines. Anthracyclines 146-160 ATP binding cassette subfamily B member 1 Homo sapiens 0-3 1355571-1 1992 Expression of multidrug resistance (mdr 1) gene, which encodes a transmembrane efflux pump referred to P-glycoprotein, leads to the decreased intracellular accumulation of various lipophilic drugs, such as vinca alkaloids, anthracyclines and epipodophyllotoxins. Anthracyclines 223-237 ATP binding cassette subfamily B member 1 Homo sapiens 36-41 1355571-1 1992 Expression of multidrug resistance (mdr 1) gene, which encodes a transmembrane efflux pump referred to P-glycoprotein, leads to the decreased intracellular accumulation of various lipophilic drugs, such as vinca alkaloids, anthracyclines and epipodophyllotoxins. Anthracyclines 223-237 ATP binding cassette subfamily B member 1 Homo sapiens 103-117 1348448-11 1992 It should be stressed, however, that these effects were substantially smaller than the effects of Pgp overexpression on the accumulation and cytotoxicity of the anthracycline daunorubicin and the epipodophyllotoxin etoposide in the same cell lines. Anthracyclines 161-174 ATP binding cassette subfamily B member 1 Homo sapiens 98-101 2304354-1 1990 The human multidrug-resistance gene (MDR1) encodes an energy-dependent multidrug efflux protein responsible for the cross-resistance of cultured cells to natural product chemotherapeutic agents such as the anthracyclines and vinca alkaloids. Anthracyclines 206-220 ATP binding cassette subfamily B member 1 Homo sapiens 37-41 1696833-5 1990 Hence high levels of MDR1 expression may explain, at least in part, the ineffectiveness of anthracycline antibiotic containing treatment regimens in some patients with AML. Anthracyclines 91-104 ATP binding cassette subfamily B member 1 Homo sapiens 21-25 1968051-0 1990 Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Anthracyclines 121-134 ATP binding cassette subfamily B member 1 Homo sapiens 22-26 1982999-2 1990 The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide. Anthracyclines 345-359 ATP binding cassette subfamily B member 1 Homo sapiens 65-79 1982999-2 1990 The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide. Anthracyclines 345-359 ATP binding cassette subfamily B member 1 Homo sapiens 189-203 1982999-2 1990 The results obtained show that: a) patients whose blasts express P-glycoprotein are resistant towards protocols including Doxorubicin, Daunorubicin, Etoposide, Mithramycin, Vincristine; b) P-glycoprotein can be expressed constitutively in some cases; c) P-glycoprotein does not appear to be the only mechanism responsible for resistance towards anthracyclines and Etoposide. Anthracyclines 345-359 ATP binding cassette subfamily B member 1 Homo sapiens 189-203 34126072-1 2021 Multidrug resistance-associated protein 7 (MRP7) is an important member of ABC transporter superfamily and has been revealed to mediate the cross-membrane translocation of a wide range of chemotherapeutic agents including taxanes, epothilones, Vinca alkaloids, Anthracyclines and Epipodophyllotoxins.In our previous study, a 1,2,3-triazole-pyrimidine hybridCMP25was synthesized and found able to efficiently reverse multidrug resistance (MDR) mediated by P-glycoprotein. Anthracyclines 261-275 ATP binding cassette subfamily B member 1 Homo sapiens 455-469 35462331-2 2022 Therapeutic outcome of the crucial anthracycline-based induction therapy often can be compromised by a resistant phenotype associated with overexpression of ABCB1 transporters. Anthracyclines 35-48 ATP binding cassette subfamily B member 1 Homo sapiens 157-162 35462331-7 2022 In line with these data, midostaurin potentiated proapoptotic processes in ABCB1-overexpressing leukemic cells when combined with anthracyclines. Anthracyclines 130-144 ATP binding cassette subfamily B member 1 Homo sapiens 75-80 35456712-5 2022 The variant alleles of ABCB1 were related to anthracycline intracellular accumulation, increasing complete remission, survival and toxicity. Anthracyclines 45-58 ATP binding cassette subfamily B member 1 Homo sapiens 23-28 2692650-10 1989 Some findings suggest that GP 170 is a transport protein for cytotoxic hydrophobic drugs like the anthracyclines. Anthracyclines 98-112 ATP binding cassette subfamily B member 1 Homo sapiens 27-33 35402005-3 2022 We investigate the incidence of hematological toxicities and their relation to the haplotype ATP-binding cassette B1 (ABCB1) which were polymorphisms of C1236T, C3435T, G2677T, and glutathione S-transferase P1 (GSTP1) A313G genes in Indonesian breast cancer patients who received anthracycline during chemotherapy. Anthracyclines 280-293 ATP binding cassette subfamily B member 1 Homo sapiens 93-116 35402005-3 2022 We investigate the incidence of hematological toxicities and their relation to the haplotype ATP-binding cassette B1 (ABCB1) which were polymorphisms of C1236T, C3435T, G2677T, and glutathione S-transferase P1 (GSTP1) A313G genes in Indonesian breast cancer patients who received anthracycline during chemotherapy. Anthracyclines 280-293 ATP binding cassette subfamily B member 1 Homo sapiens 118-123